Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non–Small-Cell Lung Cancer: A Phase-Ii Study

Journal of Thoracic Oncology - United States
doi 10.1097/jto.0b013e3182519d79
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Treatment Paradigms for Patients With Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line

Current Oncology
Oncology
2012English

Erlotinib Treatment in Pretreated Patients With Non-Small Cell Lung Cancer: A Phase II Study

Oncology Letters
Cancer ResearchOncology
2010English

A Phase II Study of High Dose Epirubicin in Unresectable Non Small Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
1992English

ARCTIC: Durvalumab With or Without Tremelimumab as Third-Line or Later Treatment for Metastatic Non-Small Cell Lung Cancer

Annals of Oncology
MedicineOncologyHematology
2020English

Immunotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

A Phase Ib/Ii Study of HER3-targeting Lumretuzumab in Combination With Carboplatin and Paclitaxel as First-Line Treatment in Patients With Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

ESMO Open
Cancer ResearchOncology
2019English

Treatment Results Including More Than Third-Line Chemotherapy for Patients With Advanced Non-Small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2010English

Anlotinib Combined With S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial

Asian Pacific Journal of Cancer Prevention
2019English

Phase II Study of Gemcitabine Plus Oxaliplatin as First-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy